Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
50% retrace from last 4-bag bull run to $5.00 pps
nice loading zone
BAF iBio
AJMHO
IBIO is toast. How embarrassing for anyone that was touting this for years down from $2750, through 3 reverse splits.
Investors should file a class action against these stock touters, that are still at it and recoup some token dollars.
Shorting this from $2750 down to 1 was a 2750 bagger and peeps and tutes have the fake stock analyst to thank for it.
adding a few here…
$iBio
Well that pump didn't last long by the fake stock analyst. Back to being 99.9% down.
Will IBIO be under a $1 in 3 months? I guess it depends on whether they do their FOURTH reverse split but then.
COULD BE UNDER $1 WITHIN 3 MONTHS...IMO
down another 12%
garbage stock run by poor mgt ..IMO
up 3 bags - how is this bad...?
company did a bad financing which will drive this DOWN...IMO
under $1 within 6 months....IMO
Printing $2.88 and down 30%
Pumper IBIO harder fake stock ANALyst and try to sucker other noobs to take a 99.999% loss
here speak to the hand....
one's conversation will be much better received and go much further when one does so
IMHO iBio will do just fine without the mindless rants & staged 'attention getting' antic's of Redspudda
or those of his faithful sidekick companion Joey-the-Forkit-Bolo lap dog
iBio - on the AI and Obesity hot ticket prowel
yes I know I know - looking at that recent iBio 4-bagger chart makes one sick to their stomach
...and rightfully so folks...!
Warning: now taking out a can of iBio Knuckles Brand Whoop-Ass...!
MOO slow brains
As a IBIO Investor
Don't be imitated by the fake stock analysts that promoted the stock and the CEO from $2,750 down to a buck
He's shitting in is bunny suit the damage of 1000's of investors that lost billions.
Go ahead and take his NJ house
All you have to do is call any class action lawyer and mention IBIO and his name (they know him)
Tell them to run a trace on JPetroInc that was telling you to BUY BUY BUY from $2750 down to a $1
Now he's leading the pump...
We WILL get mONEY back
If you were damage, take action
WARNING
Someone posing as stock analyst that bought in BIGLY at $2750 and was a BIG dope that average down and blew thought the kids college funds and a reverse mortgage...
...is trying hard to trick noob investors, as donkey as it seems, to buy his $2750 shares he invested the college fund to.
I know you've seen it 1000 times before. When cornered the excuse is...
everyone one else was lying, cheating, stealing, and breaking the law
No, just you and have posted 100s showing it
Why else would a dummy blow up a stock board, eh?
I live in his head rent free.
Funny I get notified every time someone replies to my posts. Even when I Block. Can iHub do anything about these PnDers?
Usually 5-10 times when they respond too quick and have to edit 10 more times because of anger
Anyone posting as a stock analyst it's best to do DD on
This clown got on every conference call he could posing as a stock analyst trying to mirror a billion dollar company to get on those calls.
Do your own DD. He's been a stock analyst poser on many board for 10+ years pumping junk stocks
#IHateDaddyMaid4Ever
https://www.truepeoplesearch.com/find/person/pxu4ll89lrl44290uu0n0
It still would be illegal if he was a good fake stock analyst but the track record is just horrendous on all stocks. He seems to get suckered into stocks that peak. Example...
IBIO was $2,740 presplit on July 24, 2020. That was the peak on a Friday. Nothing more stupid than buying on the next Monday or Tuesday and averaging down for almost 4 years to a $1
Those 4,000 shares are now 8 using 'simple math'. Share price of $4 x 8 shares = $32
Prolly can make bank shorting every stock the 'stock analyst' posts on social media to Buy Buy Buy. I BIO isn't the only stock he said that. What a short that would with a sell as $20K and then cover at $8
Here's a couple of the many posts from the fake stock analyst telling people to BUY BUY BUY IBIO, without a license or any kind of disclosure. He admits he said to Buy Buy Buy. I hope the SEC brings the full weight of justice down on this one. But...
That is bad enough, but add that to actually getting on multiple investor conference calls and pretending to be a stock analyst. The fake stock analyst also has a bunch of email accounts. Seems like everything he accuses others of doing, he actually does, but works OT to try to deflect.
Some people that bet the house buying at $20K a share presplit think they can pretend to be a stock analyst, say anything and get away with it. The funny part is seeing dozens of posts how how he bought more all the way done. Dozens.
If he did, the fake stock analyst must have catastrophic losses or he was lying. Would be funny if he posted the shares he actually still owns and didn't already dump for a catastrophic loss. That would be a start to disclosures stock analysts are 'supposed to' do.
$AGBA next
bring em JOEY bring em...!
you know what "Burner Phone Joey" - you can't - because there is no case "JOEY" - Duh...!
iBio going to do just fine - but you...?
nobody believes peeps who post these public messages about themselves - how utterly pathetic Sporto
SMH - you can't make this shite up folks
MOO laughing stock
The fake stock analyst may have more to worry about than his IBIO and MONI investments. I hear rumors the SEC gonna come calling. They now have the full audio files of both recordings where the fake analyst was sputtering and stammering like a buffoon. I wonder if they will buy the excuse that the host made an error, and the fake analyst didn't know how they would use his company name when he provided it. See, that might work for the first call, but the buffoon provided his company name AGAIN a year later on the second call. That excuse won't work for the second violation.
And then there's the records of the conference calls the fake analyst called into, again providing his company name JWP Incorporated, and didn't get selected on the Q&A part. I wonder how many of those calls exist that we don't even know about. SEC will get to the bottom of it. All the IMO's and other lame statements attached to postings here won't matter.
Whose gonna come knocking at the door first? JFB or the SEC. Maybe both at the same time? Wouldn't that be a riot. Of course, full video would be posted on all the boards where the fake analyst posts. I also heard from a friend that the fake analyst was likely in contact with Mr. Napadano, the analyst who covered AMBS who went to prison for fraud. SEC looking into that report as well. Fake analyst says he's contacted a detective regarding my post to come to NJ for a visit. He might be better off contacting his attorney. But he's too brash for that. Ooh-Rah!
Wishing a Happy Easter to IBIO investors. I hope your investment here is successful. Beware of anything posted by the fake analyst from JWP Inc. Follow his posts and see a dismal track record of investment success. Pretty much no success anywhere, ever. That $20K initial investment in IBIO prior to the 3 RS's is typical. You might want to reconsider investing in IBIO if this clown is invested here and pumping the stock.
Fake analyst buffoon claims this is me. There are a few problems:
1. I don't live in Miami and never have.
2. Wrong eye color.
3. I'm not bald and don't shave my head.
3 strike strike-out. Or 3 more 💩 thrown at a wall to see if something sticks. Massively incompetent DD this fake analyst churns out. If I had a dollar for every person he claims me to be... I could buy some IBIO and MONI and wait for that investment to turn into about 1.2 cents. 🙀
Holy Crap!
iBio Shares Outstanding: 3.484M
And they just unloaded 5,287,278 shares and had to give away 5,287,278 warrants?
Oh the dilution!
The pumping stock analyst that gives out financial advice without a license prolly forgot with all those massive reverse splits, IBIO didn't split the AS.
Is the Authorized Share still 275,000,000?
No wonder why 'tutes' are dumping IBIO right and left. IBIO can dilute this into oblivion and as a BIO with no revenue and nothing in trials, guess what will happen.
Check out the 'tutes' that dumped it.
https://fintel.io/so/us/ibio
IBIO diluted the crap out of investors and now the one that was giving financial advice on social media without a license and proper disclosures is back at it? Investors are down 99.99% and he's all giddy about it?
The stock analyst must be bad with 'simple' math
As you pointed out, share of IBIO without the RSs is worth $0.0002
Current $4 is equal to $0.0008
Wowee the sp moved from $0.0002 to $0.0008 presplit for anyone that was betting on a dead cat bouncing. Lets throw a tickertape parade on Monday.
BTW: The stock analyst 'said' he was averaging down from $20,000 BIGLY so must have bet the farm and now can recoup a tiny fraction.
I thought I was Warp. Now you're claiming I am MiamiMark? Are we all the same person? I see you continue to throw more of your turds 💩 at the wall hoping something will stick.
Red and I take great pleasure in reading your ridiculous claims. The lack of any real analytical or investigative skills is stunning, especially with multiple investor calls trying to sound like an analyst. That's the crown jewel. MULTIPLE CALLS. Yeah, they made an error, right? LMFAO
***** 5 Star Post *****
I have my idea's about OS investment dollars still invested on both sides of iBio's box
if I'm correct, we have many more runs coming - all on the heels of Brennans' RubrYc IP Platform success
AJMHO
yo Joey-the-Forkey-Bollo - shows up right on time as usual - yes sirrheee bob...!
I suspect you see the glass 1/2 empty while I see the glass 1/2 full - and getting fuller all the time with iBio's success - eh JOEY...?
I assure you - iBio exciting times are ahead pal...!
but unfortunately and sad to say for some novice and noob by-stander and non-investing investors, they missed "loading zone" boat - when others were "buy-buy-buying" and averaging down on their 'mother load'
which is now up substantially - and in positive territory - how do you like dem apples...?
unfortunately, I guess its more important for some to waste time posting how to use fake IP's, burner phones and multiple fake email addresses:
but here, let me help you with a lil "Math 101" with this below formula:
VWAP x VOLUME = TRADE VAL
so what this means is the following 3/4-Mil. $$$ sum is the total "dollas" that traded hands in 3 days time - in simplified terms for you, of course:
$221,546,817.90
$500,040,412.67
$854,201.98
______________
$722,441,532.55
now can you calculate what the "float churn" was for the 3 day running-spree which netted a 4-bagger for us iBio's SH's...?
and here is yet another simplified chart for your easy reading eyes to feast upon:
that's one hell of an amount of incoming dollas, aka money - which primarily states iBio has something going on - eh JOEY - or is it MiamiMark - oye veh...!
and I would also suspect it has something to do with clean PP funding, convertible lock-up, high strike price agreement, as well as...
RubrYc's IA Platform, substantial IP test results thus far, and the new biopharma collaboration in Obesity IP development, amount other milestone deliverables...
next time we'll discuss what non-milestone deliverables are and how investing in a twice failed Stanford U. "Financial Engineer" CEO hack
not once but twice over - will lead to loosing all your investment dollas
iBio's Can-O-Whoop Arse for yhee:
gots to go sporto, the Easter Bunny is a-knockin - cheers brah...!
MOO bad brains
Share price only has to get back to $20,000 per share for someone who bought 5000 shares at $4 (adjusting for the 3 reverse splits since then) to break even. Those 5000 shares were reduced to 500 shares, then to 20 shares, then to 1 share. All the while the buyer was posting BUY BUY BUY on this board. Maybe the buyer averaged down and now only needs $2,000 per share to break even.
Good to be excited about the stock again after many months of silence, I suppose. 💩
$IBIO is a PRIME example
— maverick_1 (@maveric92283613) March 28, 2024
of how the conventional view of a Reverse Split can be WRONG https://t.co/4ivyaXAxmR
AND MASSIVE NAKED COVERING
AND 2 Financings+ extension in last 4 months can LIFT w/NEWS
MASSIVE NAKED COVERING & $PIPE
#DISRUPTOR #CANCER $NWBO #SPOOFING
— maverick_1 (@maveric92283613) March 28, 2024
Collabs $MRK $AZN $AMGN $REGN $TAK $BMY $JNJ $GILD $RHHBY$IBIO
NAKED COVERING!
Creative Financing(VC beats)
1 yr CHART!
ALL to SELF LEARN vs rely
re Complex BioTech VOLATILITYhttps://t.co/PoInslWKBT$NWBO 4 Gen $https://t.co/8ejEw00NgA
DXYZ is a real beast..26.91 another gcts maybe
IBIO - Up bigly in pre-market.
iBio current Market Cap - $11.71M
iBio current Shares in Issue = 3.45 Mil. Float
iBio with their RubrYc AI Platform and hunting Obesity could easily be worth $100-Mil MC
thats a 10 x bagger from here
if anyone saw the float churn monetary value yesterday
its patently clear there are serious $$$ players at the iBio craps table - but then again - there's nothing new there
may well be Ken Dart is still sitting pretty with chips
AJMHO
MM 164 for you Sir...
BAF iBio...!
IBIO: This puppy ain't done yet --- and still very LOW-priced, compared to all of the already much HIGHER-priced stuff nevertheless soaring to HUNDREDS of percentages anyway!! (Wall Street is SMOKIN'!!)
Printing $4.10 AH's
BAF iBio...!
MOO
IBIO: Witty, Dude!! OBESE, indeed, but in the RIGHT places!!
the amount of shares churned today was "OBESE"
3.5-Mil. share "low floater" running in the beginning stages of an epic year my friend...
MOO
IBIO: It was great news. (And heck, just mention that word OBESITY behind a STOCK in the USA these days, & any 'Call Letters' might garner a 3-bagger return!!)
yo Redspudda
hope you and your alter-ego Moshe were buying at the bottom sporto
lolzzz
MOO ding a ling
iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
March 27 2024 - 07:00AM
https://ih.advfn.com/stock-market/AMEX/ibio-IBIO/stock-news/93558575/ibio-and-astralbio-announce-transformative-ai-drug
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) announces today that it has entered into a collaboration agreement with AstralBio, Inc. (“AstralBio”) to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions.
Yesterday, iBio announced the closing of a $15 million private placement financing with ADAR1 Capital Management, Lynx1 Capital Management, Ikarian Capital and other institutional investors. The company will use a portion of the net proceeds to support new partnerships, such as this collaboration with AstralBio.
The goal of this transformative collaboration is to rapidly build a novel, best-in-class cardiometabolic disease portfolio by combining iBio’s ability to create antibodies against hard-to-drug targets with AstralBio’s significant biologics experience and drug development expertise. As part of the collaboration, iBio has granted an exclusive license to its AI-powered technology to identify and engineer four (4) targets for the treatment of cardiometabolic disease, of which AstralBio may continue the pre-clinical development and deploy its proven drug development expertise to advance candidates to an Investigational New Drug (IND) application. iBio has the exclusive option to license three (3) cardiometabolic targets from AstralBio and will receive the rights to develop, manufacture and commercialize those targets upon exercise. As a result of this collaboration, iBio and AstralBio have agreed to initiate the development of a novel lead program focused on targeting the transforming growth factor beta (TGFb) superfamily for the treatment of muscle wasting and obesity. Upon mutual consent, the parties may also expand the collaboration to include additional targets in other fields.
“We are confident our AI-enabled technology is exceptionally well positioned to develop antibodies against challenging targets in the cardiometabolic space,” said iBio’s Chief Executive Officer and Chief Scientific Officer, Martin Brenner, DVM, Ph.D. “The future of treating millions of patients affected by obesity and cardiometabolic disease globally will rely on next generation therapies aimed at enhancing both the efficacy and the tolerability profiles of current treatments. Notably, the collaboration’s lead program targeting the TGFb superfamily is designed to achieve a best-in-class profile. Our approach, which combines AI-driven epitope steering with the StableHu antibody optimizer and mammalian display, aims to validate proof of concept studies that underscore the immense potential of anti-myostatin strategies. Over the coming months, we expect to announce additional novel targets, each promising a similarly transformative profile.”
Dr. Brenner added, “Leveraging my experience in obesity and cardiometabolic disease drug development from my time at Eli Lilly and Pfizer, I am eager to advance potentially groundbreaking compounds through our partnership with AstralBio, a team renowned for its entrepreneurship and track record to develop best-in-class and first-in-class therapies.”
“We are excited to collaborate with the talented iBio team to rapidly advance exciting targets in cardiometabolic disease and beyond. Using machine learning tools in the discovery of biological drugs has the potential to shorten development timeframes and lower expenses while enhancing the likelihood of successful development. We look forward to working with iBio to mutually advance our goals to deliver meaningful precision therapies for patients efficiently,” said Patrick Crutcher, AstralBio’s Co-founder and Chief Executive Officer.
About iBio
iBio is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for obesity, cardiometabolic, hard-to-target cancers, and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information, visit www.ibioinc.com.
About AstralBio
AstralBio is a privately held biotechnology company founded by Patrick Crutcher and several former team members of ValenzaBio and AlmataBio. AstralBio's mission is to develop first-in-class or best-in-class medicines to treat cardiometabolic and immune-mediated diseases. The company plans to leverage iBio’s proven machine learning-enabled platform to accelerate the progression of novel therapeutic targets to transform patient care.
Webcasted Conference Call Details
iBio will host a webcasted conference call with an associated slide presentation today, March 27, at 8:30 a.m. EDT to discuss its collaboration with AstralBio.
The live and archived webcast may be accessed on the Company’s website at www.ibioinc.com under “News and Events” in the Investors section. To participate in the conference call by telephone, please pre-register via this link to receive the dial-in number and your unique PIN.
Forward-Looking Statements
Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding the intended use of proceeds, the expected gross proceeds from the offering and the expected extension of the Company’s cash runway to fund its operating plan into 2025, the ability to build a diverse set of novel best-in-class obesity treatments, the Company’s AI-enabled technology being exceptionally well positioned to develop antibodies against challenging targets in the cardiometabolic disease space, the collaboration’s lead program targeting the TGFb superfamily achieving a best-in-class profile, the size of the obesity market, aiming to pioneer antibody treatments for obesity and cardiometabolic diseases and advancing potentially groundbreaking compounds through the Company’s partnership with AstralBio. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties related to market conditions and the completion of the offering on the anticipated terms or at all, the ability to develop antibodies against challenging targets in the cardiometabolic disease space, the ability to finance when needed and the risk factors described in the Company’s Annual Report on Form 10-K for the year ended June 30, 2023, and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iBio, Inc. specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Contacts:
Investor Relations
Stephen Kilmer
iBio, Inc.
(646) 274-3580
skilmer@ibioinc.com
Media Relations
Susan Thomas
iBio, Inc.
(619) 540-9195
susan.thomas@ibioinc.com
130-Mil shares traded w/3-Mil in the float
$365k cash passing through hands and 2-1/4 hours left till closing bell
dumptins up Buchwheat ….!
MOO
$100G FOR YOUTODAY!
Followers
|
444
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
27552
|
Created
|
11/13/08
|
Type
|
Free
|
Moderators |
iBio, Inc. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field,
develops and offers pharmaceutical product applications using its iBio Technology platform.
The iBio Technology platform is a proprietary,
transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines.
https://www.ibioinc.com/about/what-we-do
Because the cell line development phase is eliminated, FastPharming offers significant time savings compared to traditional expression platforms.
For instance, iBio produces milligram quantities of protein in as little as 6 weeks, gram quantities in 3 months, and greater than 10g of cGMP material in only 8 months.Additionally,
FastPharming processes are easily scalable, produce high quality product, are cost efficient, deliver improved safety, and facilitate superior glycosylation control.
IBio uses the FastPharming System to quickly produce biotherapeutic and vaccine candidates for unmet medical needs.
In the area of human disease, IBIO-100 targets fibrosis, a leading world-wide cause of organ failure.
IBIO-200 is a virus-like particle (VLP) vaccine designed as a rapid medical countermeasure solution to the COVID-19 outbreak.
The FastPharming platform produces a variety of recombinant products including:
The traditional approach to vaccines is to use live or killed viruses to generate immune responses.
Development, approval, and commercialization of these types of vaccines can take several years, a model that is clearly unfeasible during this pandemic.
New approaches use a reductionist approach by identifying key viral components that can be incorporated into a vaccine that elicits a strong immune response and is also safe and easy to manufacture.1
Such approaches include vaccines that rely on recombinant DNA or messenger RNA (mRNA).
San Diego-based Inovio Pharmaceuticals, the first company to advance a vaccine (INO-4700) against MERS-CoV into human testing,
is developing a DNA-based vaccine against COVID-19, while both Cambridge, Massachusetts-based Moderna and German biotech CureVac are developing mRNA-based vaccines.
There are concerns with many of these approaches, however, particularly DNA and mRNA vaccines.
Questions have been raised about their cold-chain requirements compared with traditional vaccine technology platforms.
These solutions provide great hope but carry significant risk.
At present, six COVID-19 or SARS-CoV-2 phase I clinical trials are listed in clinicaltrials.gov, although there are likely more in the works, as registration in the database is not mandatory until phase II.
Virus-like particles (VLPs) represent a promising alternative to soluble antigens, as their shape, size, repetitive antigen structure,
and geometry have been shown to trigger stronger immune response, both humoral and cellular.2 VLPs are artificial
constructs comprising multiple proteins organized to resemble a virus, but without including any viral genetic material, thereby rendering them non-infectious.
Because they have the components and conformation of the native virus, they can engender stronger and broader immune responses than the antigen itself.
In addition, VLPs can be produced as cost-effectively as other novel platform technologies being used for COVID-19 vaccine development
and do not present additional safety concerns compared with those associated with DNA- and mRNA-based solutions.
iBio has extensive capability in this area, having developed plant-based bioprocesses that generate VLPs with the
same structures as more traditional methods but via more efficient manufacturing routes. VLP platforms like iBio’s are advantageous because,
in addition to obtaining high yields of the individual VLP components, the components automatically self-assemble into a spherical VLP,
simplifying both the upstream and downstream purification processes involved in VLP manufacture.
The recent phase III clinical success of a VLP-based influenza vaccine produced in the N. benthamiana system
(NCT03739112, NCT03301051), both in terms of efficacy and safety, demonstrates the potential for plant-based VLP vaccine development.3
IBIO-200 is iBio’s lead COVID-19 vaccine candidate. iBio uses Woodchuck hepatitis virus and human hepatitis B virus core proteins
fused to COVID-19 receptor-binding motif (RBM), which self-assemble into empty nanoparticles.
The resulting VLPs form 40- to 50-nm diameter nanoparticles. The antigen is displayed in a repetitive structure and geometry,
and the particle is decorated with oligomannose molecules to more closely resemble the structure of naturally occurring viruses.
Oligomannose glycosylation is thought to lead to better cellular uptake of the VLPs by antigen-presenting cells via the mannose receptor.
As with other VLP-derived vaccines, IBIO-200 is designed to interact with immune cells differently than soluble antigens.
The production of IBIO-200 follows standard and highly optimized protocols. Plants are seeded,
germinated, and grown to 5 weeks of age in environmentally controlled grow rooms.
At 5 weeks, plants are vacuum infiltrated with Agrobacterium containing transient plant-specific expression vectors encoding COVID-19 antigen constructs.
After infiltration, the vector drives vaccine expression for 5–7 days; plant material is shredded, and total soluble protein extracted.
Preliminary scalable downstream processes have been designed, including concentration and buffer exchange of clarified extract capture and polishing chromatography.
For evaluation purposes, the first screenings measured expression and protein stability.
Selected candidates will then be injected into mice for an initial immunization study.
IgG response, cytokine profiling, and results of virus neutralization assays will dictate a second candidate screening.
Subsequently, selected candidates will enter toxicology studies in appropriate animal models to support an IND filling.
A lead candidate and a back-up will then be selected for further in vivo efficacy studies.
In parallel, iBio will develop a process that is scalable to cGMP manufacturing, prepare manufacturing documentation, and develop QC release assays.
The FastPharming manufacturing system delivers a tightly controlled particle size, providing considerable quality and scale-up advantages,
as uniform antigen display enables better dose definition and higher product yields.
All of this work will be based on technology proven successful for the clinical development of vaccine candidates in iBio’s U.S.-based,
large-scale production facility with all cGMP, QA, QC, scale-up, and regulatory resources;
the facility is self-contained and secure with highly reliable logistics.
iBio’s FastPharming facility was originally constructed in 2010 with funding from the Defense Advanced Research Projects Agency (DARPA),
part of the U.S. Department of Defense (DoD), which was exploring a range of technologies that could enable faster responses to outbreaks.
Plant-based expression technology won out, and the facility was one of three commercial sites comprising the “Blue Angel” initiative.
As part of the DARPA Blue Angel H1N1 Program, iBio’s facility was designed and built to manufacture kilogram quantities of
recombinant proteins within months versus the historically longer time frames needed for more traditional systems.
Its rapid launch to production has been designed specifically for medical countermeasure responses.
The iBio facility is among the largest biotherapeutic production facilities in the world for the production of recombinant protein in N. benthamiana,
with a current capacity to produce bulk clinical protein at the scale of approximately 500 million doses per year.
iBio technology has been used to produce a number of prophylactic vaccines, including soluble pathogen antigens formulated with adjuvants against anthrax,
H5N1 influenza, H1N1 influenza and hookworm, and a virus-like particle (VLP) formulated with an adjuvant against malaria.
Phase I clinical studies have been completed for all of these vaccine candidates.
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |